November 2018 FDA Recall Drug by Sandoz, Inc
D-0359-2019 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Sandoz, Inc on November 1, 2018 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in OH, PR and the recall is currently ongoing.

Recall Number: D-0359-2019

Reason for Recall
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Initiated
11-01-2018
Reported
12-05-2018
Quantity
170 HDPE bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Sandoz Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 1000-count bottles, Rx Only, Finished Drug Product Manufactured by: Lek Pharmaceuticals d.d. SI-1526 Ljubljana,Sovenia for Sandoz Inc., Princeton, NJ 08540, NDC 0781-5207-10.

Batch or Lot Expiration Information

Lot# : JB8912; Exp. 06/2020